Last week, our client Breye Therapeutics announced the appointment of Dr Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors. It also launched its new website and LinkedIn page.
Breye is a clinical-stage biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to Diabetic Retinopathy (DR) or Age-Related Macular Degeneration (AMD).
The Company’s lead compound, danegaptide, is an oral investigational drug that targets diabetic retinopathy, a complication of diabetes that can lead to blindness. Unlike the current standard of care, which involves painful and invasive injections directly into the eye, danegaptide can be taken orally and has been shown to be safe and effective in clinical studies. In addition, Breye is also developing an oral P2x7R inhibitor for AMD which seeks to reduce nerve damage and inflammation.
Breye’s new appointments come as the Company looks to prepare these assets for later stages of clinical development and expand its pipeline. Peter and Gabriela both bring extensive experience in ophthalmology drug development – Peter was previously VP and Head of Ophthalmology Research at GSK and held executive roles at ProQR and Tenpoints Therapeutics, while Gabriela has held leadership roles at both Roche and Novartis.
With backing from Novo Holdings and Sound Bioventures, Breye is well positioned to continue its research and development efforts and as the Company continues to expand its team and advance its pipeline, it will be exciting to see the impact that its innovative approach to drug development will have on ophthalmology.